title: Continued inhibition of radiographic progression in patients with psoriatic arthritis following 2 years of treatment with etanercept.
abstract: OBJECTIVE
  Clinical and radiographic responses were evaluated in patients with psoriatic arthritis (PsA) treated for up to 2 years with etanercept.
  
  
  METHODS
  Patients were previously randomized to receive placebo or etanercept in a double-blind study and chose to participate in the current open-label extension phase. All patients received etanercept 25 mg twice weekly. Radiographic progression was determined at baseline, 1 year, and 2 years using the Sharp method modified to include joints frequently affected in PsA. Arthritis and psoriasis responses were determined using American College of Rheumatology 20% (ACR20) improvement criteria, PsA response criteria (PsARC), and the psoriasis area severity index (PASI).
  
  
  RESULTS
  Of 205 patients randomized, 169 entered open-label, and 141 [71 randomized to receive placebo (placebo/etanercept) and 70 randomized to receive etanercept (etanercept/etanercept)] had radiographic data available for analysis at 2 years. ACR20 criteria, PsARC, and PASI 50 criteria were met by 64%, 84%, and 62%, respectively, of etanercept/etanercept patients at the end of the 48-week open-label period. Placebo/etanercept patients achieved comparable results within 12 weeks that were sustained at 48 weeks (63%, 80%, and 73%). Radiographic progression was inhibited in the etanercept/ etanercept patients (mean adjusted change in total Sharp score of -0.38 from baseline to 2 yrs). In placebo/etanercept patients, disease progression was inhibited once patients began receiving etanercept (mean adjusted change of -0.22 from 1 year to 2 years). Adverse event rates were similar to those observed during randomized phase, with only one serious adverse event deemed possibly related to etanercept.
  
  
  CONCLUSIONS
  These data demonstrate a sustained benefit of etanercept treatment, including inhibition of radiographic progression, in patients with PsA.
authors.affiliation: Seattle Rheumatology Associates, Seattle, Washington 98104, USA. pmease@nwlink.com
authors.forename: Philip J
authors.initials: PJ
authors.lastname: Mease
authors.forename: Alan J
authors.initials: AJ
authors.lastname: Kivitz
authors.forename: Francis X
authors.initials: FX
authors.lastname: Burch
authors.forename: Evan L
authors.initials: EL
authors.lastname: Siegel
authors.forename: Stanley B
authors.initials: SB
authors.lastname: Cohen
authors.forename: Peter
authors.initials: P
authors.lastname: Ory
authors.forename: David
authors.initials: D
authors.lastname: Salonen
authors.forename: Joel
authors.initials: J
authors.lastname: Rubenstein
authors.forename: John T
authors.initials: JT
authors.lastname: Sharp
authors.forename: Meleana
authors.initials: M
authors.lastname: Dunn
authors.forename: Wayne
authors.initials: W
authors.lastname: Tsuji
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D015535:Arthritis, Psoriatic / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000503:physiopathology; D001175:Arthrography; D018450:Disease Progression; D004311:Double-Blind Method; D000068800:Etanercept; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011565:Psoriasis / Q000188:drug therapy / Q000473:pathology; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use*; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D018501:Antirheumatic Agents; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D011993:Recombinant Fusion Proteins; D000068800:Etanercept